Paragraf named Business of the Year in Cambridge glory parade VUV Analytics Announces Publication of ASTM D8519-23 Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis Novadip Biosciences SA announces first pediatric patient with congenital pseudoarthrosis of the tibia undergoes implantation with NVD-003, an autologous tissue regeneration product, in Phase 1b/2a US/EU clinical trial Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections